nodes	percent_of_prediction	percent_of_DWPC	metapath
Hydralazine—CYP3A4—Temozolomide—melanoma	0.217	0.576	CbGbCtD
Hydralazine—CYP3A4—Vemurafenib—melanoma	0.119	0.316	CbGbCtD
Hydralazine—CYP3A4—Docetaxel—melanoma	0.0408	0.108	CbGbCtD
Hydralazine—AOC3—endothelium—melanoma	0.0281	0.175	CbGeAlD
Hydralazine—Pleuritic pain—Bleomycin—melanoma	0.0264	0.0613	CcSEcCtD
Hydralazine—AOC3—blood vessel—melanoma	0.0259	0.161	CbGeAlD
Hydralazine—RYR2—eye—melanoma	0.0229	0.142	CbGeAlD
Hydralazine—AOC3—eye—melanoma	0.0138	0.0857	CbGeAlD
Hydralazine—AOC3—retina—melanoma	0.0136	0.0849	CbGeAlD
Hydralazine—RYR2—head—melanoma	0.013	0.0808	CbGeAlD
Hydralazine—AOC3—mammalian vulva—melanoma	0.0109	0.068	CbGeAlD
Hydralazine—Polyneuropathy—Docetaxel—melanoma	0.00911	0.0212	CcSEcCtD
Hydralazine—Vasculitis—Vemurafenib—melanoma	0.00895	0.0208	CcSEcCtD
Hydralazine—P4HA1—mammalian vulva—melanoma	0.00873	0.0543	CbGeAlD
Hydralazine—AOC3—head—melanoma	0.00782	0.0486	CbGeAlD
Hydralazine—Hepatomegaly—Dactinomycin—melanoma	0.00698	0.0162	CcSEcCtD
Hydralazine—Digestion impaired—Temozolomide—melanoma	0.00668	0.0155	CcSEcCtD
Hydralazine—P4HA1—head—melanoma	0.00625	0.0389	CbGeAlD
Hydralazine—AOC3—lymph node—melanoma	0.00547	0.034	CbGeAlD
Hydralazine—Eosinophilia—Vemurafenib—melanoma	0.00543	0.0126	CcSEcCtD
Hydralazine—Lacrimation—Docetaxel—melanoma	0.00505	0.0117	CcSEcCtD
Hydralazine—Weight decreased—Vemurafenib—melanoma	0.00496	0.0115	CcSEcCtD
Hydralazine—Leukocytosis—Carmustine—melanoma	0.00492	0.0114	CcSEcCtD
Hydralazine—Neuropathy peripheral—Vemurafenib—melanoma	0.00479	0.0111	CcSEcCtD
Hydralazine—P4HA1—lymph node—melanoma	0.00438	0.0272	CbGeAlD
Hydralazine—Disorientation—Bleomycin—melanoma	0.0043	0.00998	CcSEcCtD
Hydralazine—Neuritis—Docetaxel—melanoma	0.00398	0.00924	CcSEcCtD
Hydralazine—Chills—Vemurafenib—melanoma	0.00394	0.00914	CcSEcCtD
Hydralazine—Vascular purpura—Temozolomide—melanoma	0.00362	0.00842	CcSEcCtD
Hydralazine—Nasal congestion—Temozolomide—melanoma	0.00356	0.00826	CcSEcCtD
Hydralazine—Purpura—Temozolomide—melanoma	0.00336	0.00781	CcSEcCtD
Hydralazine—Myalgia—Vemurafenib—melanoma	0.00325	0.00755	CcSEcCtD
Hydralazine—Arthralgia—Vemurafenib—melanoma	0.00325	0.00755	CcSEcCtD
Hydralazine—Lacrimation increased—Docetaxel—melanoma	0.00322	0.00748	CcSEcCtD
Hydralazine—RYR2—SIDS Susceptibility Pathways—POU3F2—melanoma	0.00322	0.101	CbGpPWpGaD
Hydralazine—Pancytopenia—Bleomycin—melanoma	0.00315	0.00733	CcSEcCtD
Hydralazine—Weight decreased—Bleomycin—melanoma	0.00301	0.00698	CcSEcCtD
Hydralazine—Pancytopenia—Dactinomycin—melanoma	0.00294	0.00683	CcSEcCtD
Hydralazine—Hypotension—Vemurafenib—melanoma	0.00291	0.00677	CcSEcCtD
Hydralazine—Neutropenia—Dactinomycin—melanoma	0.0029	0.00673	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Vemurafenib—melanoma	0.00284	0.0066	CcSEcCtD
Hydralazine—Haematuria—Bleomycin—melanoma	0.00282	0.00656	CcSEcCtD
Hydralazine—Pancytopenia—Carmustine—melanoma	0.00275	0.00639	CcSEcCtD
Hydralazine—Neutropenia—Carmustine—melanoma	0.00271	0.0063	CcSEcCtD
Hydralazine—Decreased appetite—Vemurafenib—melanoma	0.00271	0.00629	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Vemurafenib—melanoma	0.00269	0.00625	CcSEcCtD
Hydralazine—Constipation—Vemurafenib—melanoma	0.00267	0.00619	CcSEcCtD
Hydralazine—Pancytopenia—Temozolomide—melanoma	0.00266	0.00618	CcSEcCtD
Hydralazine—Hypoaesthesia—Bleomycin—melanoma	0.00265	0.00614	CcSEcCtD
Hydralazine—Dysuria—Temozolomide—melanoma	0.00262	0.00608	CcSEcCtD
Hydralazine—Neutropenia—Temozolomide—melanoma	0.00262	0.00608	CcSEcCtD
Hydralazine—Depression—Carmustine—melanoma	0.00258	0.00599	CcSEcCtD
Hydralazine—Agranulocytosis—Dactinomycin—melanoma	0.00258	0.00599	CcSEcCtD
Hydralazine—Weight decreased—Temozolomide—melanoma	0.00254	0.00589	CcSEcCtD
Hydralazine—Neuropathy peripheral—Carmustine—melanoma	0.00253	0.00588	CcSEcCtD
Hydralazine—Depression—Temozolomide—melanoma	0.00249	0.00579	CcSEcCtD
Hydralazine—Hepatitis—Dactinomycin—melanoma	0.00248	0.00576	CcSEcCtD
Hydralazine—Flushing—Bleomycin—melanoma	0.00247	0.00573	CcSEcCtD
Hydralazine—Body temperature increased—Vemurafenib—melanoma	0.00246	0.00572	CcSEcCtD
Hydralazine—Neuropathy peripheral—Temozolomide—melanoma	0.00245	0.00569	CcSEcCtD
Hydralazine—Chills—Bleomycin—melanoma	0.00239	0.00554	CcSEcCtD
Hydralazine—Cardiac failure congestive—Docetaxel—melanoma	0.00238	0.00552	CcSEcCtD
Hydralazine—Hypoaesthesia—Carmustine—melanoma	0.00231	0.00536	CcSEcCtD
Hydralazine—Hallucination—Carmustine—melanoma	0.00231	0.00536	CcSEcCtD
Hydralazine—Flushing—Dactinomycin—melanoma	0.0023	0.00534	CcSEcCtD
Hydralazine—Hypersensitivity—Vemurafenib—melanoma	0.0023	0.00533	CcSEcCtD
Hydralazine—Hepatitis—Temozolomide—melanoma	0.00224	0.00521	CcSEcCtD
Hydralazine—Hallucination—Temozolomide—melanoma	0.00223	0.00518	CcSEcCtD
Hydralazine—Hypoaesthesia—Temozolomide—melanoma	0.00223	0.00518	CcSEcCtD
Hydralazine—Chills—Dactinomycin—melanoma	0.00222	0.00517	CcSEcCtD
Hydralazine—Cardiac failure—Docetaxel—melanoma	0.00221	0.00513	CcSEcCtD
Hydralazine—Pruritus—Vemurafenib—melanoma	0.00221	0.00512	CcSEcCtD
Hydralazine—Flushing—Carmustine—melanoma	0.00215	0.005	CcSEcCtD
Hydralazine—Ill-defined disorder—Bleomycin—melanoma	0.00215	0.00499	CcSEcCtD
Hydralazine—Anaemia—Bleomycin—melanoma	0.00214	0.00497	CcSEcCtD
Hydralazine—Diarrhoea—Vemurafenib—melanoma	0.00213	0.00495	CcSEcCtD
Hydralazine—Malaise—Bleomycin—melanoma	0.00209	0.00485	CcSEcCtD
Hydralazine—Flushing—Temozolomide—melanoma	0.00208	0.00483	CcSEcCtD
Hydralazine—Leukopenia—Bleomycin—melanoma	0.00207	0.00481	CcSEcCtD
Hydralazine—Dizziness—Vemurafenib—melanoma	0.00206	0.00479	CcSEcCtD
Hydralazine—RYR2—Arrhythmogenic Right Ventricular Cardiomyopathy—CDH2—melanoma	0.00203	0.0636	CbGpPWpGaD
Hydralazine—Chills—Temozolomide—melanoma	0.00201	0.00467	CcSEcCtD
Hydralazine—Ill-defined disorder—Dactinomycin—melanoma	0.002	0.00465	CcSEcCtD
Hydralazine—Anaemia—Dactinomycin—melanoma	0.002	0.00463	CcSEcCtD
Hydralazine—Vomiting—Vemurafenib—melanoma	0.00198	0.0046	CcSEcCtD
Hydralazine—Myalgia—Bleomycin—melanoma	0.00197	0.00458	CcSEcCtD
Hydralazine—Rash—Vemurafenib—melanoma	0.00197	0.00457	CcSEcCtD
Hydralazine—Dermatitis—Vemurafenib—melanoma	0.00196	0.00456	CcSEcCtD
Hydralazine—Headache—Vemurafenib—melanoma	0.00195	0.00454	CcSEcCtD
Hydralazine—Discomfort—Bleomycin—melanoma	0.00195	0.00452	CcSEcCtD
Hydralazine—Malaise—Dactinomycin—melanoma	0.00195	0.00452	CcSEcCtD
Hydralazine—Cramp muscle—Docetaxel—melanoma	0.00194	0.00451	CcSEcCtD
Hydralazine—Leukopenia—Dactinomycin—melanoma	0.00193	0.00449	CcSEcCtD
Hydralazine—Tremor—Carmustine—melanoma	0.00189	0.0044	CcSEcCtD
Hydralazine—Oedema—Bleomycin—melanoma	0.00189	0.00439	CcSEcCtD
Hydralazine—Anaemia—Carmustine—melanoma	0.00187	0.00434	CcSEcCtD
Hydralazine—Agitation—Carmustine—melanoma	0.00186	0.00431	CcSEcCtD
Hydralazine—Nausea—Vemurafenib—melanoma	0.00185	0.0043	CcSEcCtD
Hydralazine—Thrombocytopenia—Bleomycin—melanoma	0.00185	0.00429	CcSEcCtD
Hydralazine—RYR2—SIDS Susceptibility Pathways—MAP2—melanoma	0.00185	0.0578	CbGpPWpGaD
Hydralazine—Myalgia—Dactinomycin—melanoma	0.00184	0.00427	CcSEcCtD
Hydralazine—Tremor—Temozolomide—melanoma	0.00183	0.00425	CcSEcCtD
Hydralazine—Discomfort—Dactinomycin—melanoma	0.00182	0.00422	CcSEcCtD
Hydralazine—Angina pectoris—Docetaxel—melanoma	0.00182	0.00422	CcSEcCtD
Hydralazine—Ill-defined disorder—Temozolomide—melanoma	0.00181	0.00421	CcSEcCtD
Hydralazine—Leukopenia—Carmustine—melanoma	0.00181	0.0042	CcSEcCtD
Hydralazine—Anaemia—Temozolomide—melanoma	0.0018	0.00419	CcSEcCtD
Hydralazine—Anorexia—Bleomycin—melanoma	0.0018	0.00418	CcSEcCtD
Hydralazine—Agitation—Temozolomide—melanoma	0.00179	0.00417	CcSEcCtD
Hydralazine—Pancytopenia—Docetaxel—melanoma	0.00177	0.00411	CcSEcCtD
Hydralazine—Hypotension—Bleomycin—melanoma	0.00177	0.0041	CcSEcCtD
Hydralazine—Oedema—Dactinomycin—melanoma	0.00176	0.00409	CcSEcCtD
Hydralazine—Malaise—Temozolomide—melanoma	0.00176	0.00409	CcSEcCtD
Hydralazine—Leukopenia—Temozolomide—melanoma	0.00175	0.00406	CcSEcCtD
Hydralazine—Neutropenia—Docetaxel—melanoma	0.00174	0.00405	CcSEcCtD
Hydralazine—Palpitations—Temozolomide—melanoma	0.00173	0.00401	CcSEcCtD
Hydralazine—Thrombocytopenia—Dactinomycin—melanoma	0.00172	0.00401	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Bleomycin—melanoma	0.00172	0.004	CcSEcCtD
Hydralazine—Myalgia—Carmustine—melanoma	0.00172	0.00399	CcSEcCtD
Hydralazine—Anxiety—Carmustine—melanoma	0.00171	0.00398	CcSEcCtD
Hydralazine—Paraesthesia—Bleomycin—melanoma	0.0017	0.00394	CcSEcCtD
Hydralazine—Weight decreased—Docetaxel—melanoma	0.00169	0.00391	CcSEcCtD
Hydralazine—Dyspnoea—Bleomycin—melanoma	0.00168	0.00391	CcSEcCtD
Hydralazine—Anorexia—Dactinomycin—melanoma	0.00168	0.0039	CcSEcCtD
Hydralazine—Myalgia—Temozolomide—melanoma	0.00166	0.00386	CcSEcCtD
Hydralazine—Arthralgia—Temozolomide—melanoma	0.00166	0.00386	CcSEcCtD
Hydralazine—Anxiety—Temozolomide—melanoma	0.00166	0.00385	CcSEcCtD
Hydralazine—Oedema—Carmustine—melanoma	0.00165	0.00383	CcSEcCtD
Hydralazine—Discomfort—Temozolomide—melanoma	0.00164	0.00381	CcSEcCtD
Hydralazine—Decreased appetite—Bleomycin—melanoma	0.00164	0.00381	CcSEcCtD
Hydralazine—Neuropathy peripheral—Docetaxel—melanoma	0.00163	0.00378	CcSEcCtD
Hydralazine—Jaundice—Docetaxel—melanoma	0.00162	0.00376	CcSEcCtD
Hydralazine—Conjunctivitis—Docetaxel—melanoma	0.00161	0.00375	CcSEcCtD
Hydralazine—Thrombocytopenia—Carmustine—melanoma	0.00161	0.00375	CcSEcCtD
Hydralazine—Tachycardia—Carmustine—melanoma	0.00161	0.00374	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Dactinomycin—melanoma	0.00161	0.00373	CcSEcCtD
Hydralazine—Oedema—Temozolomide—melanoma	0.00159	0.0037	CcSEcCtD
Hydralazine—Anorexia—Carmustine—melanoma	0.00157	0.00365	CcSEcCtD
Hydralazine—RYR2—SIDS Susceptibility Pathways—TP73—melanoma	0.00157	0.0492	CbGpPWpGaD
Hydralazine—RYR2—Arrhythmogenic Right Ventricular Cardiomyopathy—ITGA4—melanoma	0.00156	0.0489	CbGpPWpGaD
Hydralazine—Thrombocytopenia—Temozolomide—melanoma	0.00156	0.00362	CcSEcCtD
Hydralazine—Feeling abnormal—Bleomycin—melanoma	0.00156	0.00361	CcSEcCtD
Hydralazine—Agranulocytosis—Docetaxel—melanoma	0.00155	0.0036	CcSEcCtD
Hydralazine—Hypotension—Carmustine—melanoma	0.00154	0.00358	CcSEcCtD
Hydralazine—Decreased appetite—Dactinomycin—melanoma	0.00153	0.00356	CcSEcCtD
Hydralazine—Anorexia—Temozolomide—melanoma	0.00152	0.00353	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Carmustine—melanoma	0.0015	0.00349	CcSEcCtD
Hydralazine—Urticaria—Bleomycin—melanoma	0.0015	0.00348	CcSEcCtD
Hydralazine—Body temperature increased—Bleomycin—melanoma	0.00149	0.00347	CcSEcCtD
Hydralazine—Hepatitis—Docetaxel—melanoma	0.00149	0.00346	CcSEcCtD
Hydralazine—Hypoaesthesia—Docetaxel—melanoma	0.00148	0.00345	CcSEcCtD
Hydralazine—Paraesthesia—Carmustine—melanoma	0.00148	0.00344	CcSEcCtD
Hydralazine—Dyspnoea—Carmustine—melanoma	0.00147	0.00341	CcSEcCtD
Hydralazine—Feeling abnormal—Dactinomycin—melanoma	0.00145	0.00337	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Temozolomide—melanoma	0.00145	0.00337	CcSEcCtD
Hydralazine—RYR2—Arrhythmogenic Right Ventricular Cardiomyopathy—ITGAV—melanoma	0.00144	0.0451	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—ABCB5—melanoma	0.00143	0.0449	CbGpPWpGaD
Hydralazine—Decreased appetite—Carmustine—melanoma	0.00143	0.00333	CcSEcCtD
Hydralazine—Paraesthesia—Temozolomide—melanoma	0.00143	0.00332	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Carmustine—melanoma	0.00142	0.00331	CcSEcCtD
Hydralazine—Dyspnoea—Temozolomide—melanoma	0.00142	0.0033	CcSEcCtD
Hydralazine—Constipation—Carmustine—melanoma	0.00141	0.00327	CcSEcCtD
Hydralazine—Dyspepsia—Temozolomide—melanoma	0.0014	0.00326	CcSEcCtD
Hydralazine—Body temperature increased—Dactinomycin—melanoma	0.00139	0.00323	CcSEcCtD
Hydralazine—Hypersensitivity—Bleomycin—melanoma	0.00139	0.00323	CcSEcCtD
Hydralazine—Decreased appetite—Temozolomide—melanoma	0.00139	0.00322	CcSEcCtD
Hydralazine—Flushing—Docetaxel—melanoma	0.00138	0.00321	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Temozolomide—melanoma	0.00138	0.00319	CcSEcCtD
Hydralazine—Constipation—Temozolomide—melanoma	0.00136	0.00316	CcSEcCtD
Hydralazine—Feeling abnormal—Carmustine—melanoma	0.00136	0.00316	CcSEcCtD
Hydralazine—Chills—Docetaxel—melanoma	0.00134	0.00311	CcSEcCtD
Hydralazine—Pruritus—Bleomycin—melanoma	0.00134	0.0031	CcSEcCtD
Hydralazine—Feeling abnormal—Temozolomide—melanoma	0.00131	0.00305	CcSEcCtD
Hydralazine—RYR2—Arrhythmogenic Right Ventricular Cardiomyopathy—ITGB1—melanoma	0.00131	0.041	CbGpPWpGaD
Hydralazine—Body temperature increased—Carmustine—melanoma	0.0013	0.00303	CcSEcCtD
Hydralazine—Hypersensitivity—Dactinomycin—melanoma	0.0013	0.00301	CcSEcCtD
Hydralazine—Urticaria—Temozolomide—melanoma	0.00127	0.00294	CcSEcCtD
Hydralazine—Body temperature increased—Temozolomide—melanoma	0.00126	0.00293	CcSEcCtD
Hydralazine—Muscle spasms—Docetaxel—melanoma	0.00125	0.0029	CcSEcCtD
Hydralazine—Hypersensitivity—Carmustine—melanoma	0.00121	0.00282	CcSEcCtD
Hydralazine—Diarrhoea—Dactinomycin—melanoma	0.00121	0.0028	CcSEcCtD
Hydralazine—Vomiting—Bleomycin—melanoma	0.0012	0.00279	CcSEcCtD
Hydralazine—Anaemia—Docetaxel—melanoma	0.0012	0.00279	CcSEcCtD
Hydralazine—Rash—Bleomycin—melanoma	0.00119	0.00277	CcSEcCtD
Hydralazine—Dermatitis—Bleomycin—melanoma	0.00119	0.00276	CcSEcCtD
Hydralazine—Hypersensitivity—Temozolomide—melanoma	0.00117	0.00273	CcSEcCtD
Hydralazine—Leukopenia—Docetaxel—melanoma	0.00116	0.0027	CcSEcCtD
Hydralazine—Palpitations—Docetaxel—melanoma	0.00115	0.00266	CcSEcCtD
Hydralazine—RYR2—Arrhythmogenic Right Ventricular Cardiomyopathy—ITGB3—melanoma	0.00114	0.0355	CbGpPWpGaD
Hydralazine—Diarrhoea—Carmustine—melanoma	0.00113	0.00262	CcSEcCtD
Hydralazine—Pruritus—Temozolomide—melanoma	0.00113	0.00262	CcSEcCtD
Hydralazine—Nausea—Bleomycin—melanoma	0.00112	0.00261	CcSEcCtD
Hydralazine—Vomiting—Dactinomycin—melanoma	0.00112	0.0026	CcSEcCtD
Hydralazine—Rash—Dactinomycin—melanoma	0.00111	0.00258	CcSEcCtD
Hydralazine—Arthralgia—Docetaxel—melanoma	0.00111	0.00257	CcSEcCtD
Hydralazine—Myalgia—Docetaxel—melanoma	0.00111	0.00257	CcSEcCtD
Hydralazine—Dizziness—Carmustine—melanoma	0.00109	0.00253	CcSEcCtD
Hydralazine—Diarrhoea—Temozolomide—melanoma	0.00109	0.00253	CcSEcCtD
Hydralazine—Oedema—Docetaxel—melanoma	0.00106	0.00246	CcSEcCtD
Hydralazine—Dizziness—Temozolomide—melanoma	0.00105	0.00245	CcSEcCtD
Hydralazine—Vomiting—Carmustine—melanoma	0.00105	0.00243	CcSEcCtD
Hydralazine—Nausea—Dactinomycin—melanoma	0.00105	0.00243	CcSEcCtD
Hydralazine—Rash—Carmustine—melanoma	0.00104	0.00241	CcSEcCtD
Hydralazine—Dermatitis—Carmustine—melanoma	0.00104	0.00241	CcSEcCtD
Hydralazine—Thrombocytopenia—Docetaxel—melanoma	0.00104	0.00241	CcSEcCtD
Hydralazine—Tachycardia—Docetaxel—melanoma	0.00103	0.0024	CcSEcCtD
Hydralazine—Headache—Carmustine—melanoma	0.00103	0.0024	CcSEcCtD
Hydralazine—Vomiting—Temozolomide—melanoma	0.00101	0.00235	CcSEcCtD
Hydralazine—Anorexia—Docetaxel—melanoma	0.00101	0.00235	CcSEcCtD
Hydralazine—Rash—Temozolomide—melanoma	0.001	0.00233	CcSEcCtD
Hydralazine—Dermatitis—Temozolomide—melanoma	0.001	0.00233	CcSEcCtD
Hydralazine—Headache—Temozolomide—melanoma	0.000998	0.00232	CcSEcCtD
Hydralazine—RYR2—Transmembrane transport of small molecules—ARL2—melanoma	0.000994	0.0311	CbGpPWpGaD
Hydralazine—Hypotension—Docetaxel—melanoma	0.00099	0.0023	CcSEcCtD
Hydralazine—Nausea—Carmustine—melanoma	0.000979	0.00227	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Docetaxel—melanoma	0.000965	0.00224	CcSEcCtD
Hydralazine—RYR2—Calcium Regulation in the Cardiac Cell—GNA11—melanoma	0.000961	0.0301	CbGpPWpGaD
Hydralazine—Paraesthesia—Docetaxel—melanoma	0.000952	0.00221	CcSEcCtD
Hydralazine—Nausea—Temozolomide—melanoma	0.000946	0.0022	CcSEcCtD
Hydralazine—Dyspnoea—Docetaxel—melanoma	0.000945	0.00219	CcSEcCtD
Hydralazine—Dyspepsia—Docetaxel—melanoma	0.000933	0.00217	CcSEcCtD
Hydralazine—Decreased appetite—Docetaxel—melanoma	0.000921	0.00214	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Docetaxel—melanoma	0.000915	0.00212	CcSEcCtD
Hydralazine—Constipation—Docetaxel—melanoma	0.000906	0.0021	CcSEcCtD
Hydralazine—RYR2—Calcium Regulation in the Cardiac Cell—GNAQ—melanoma	0.000893	0.0279	CbGpPWpGaD
Hydralazine—Feeling abnormal—Docetaxel—melanoma	0.000873	0.00203	CcSEcCtD
Hydralazine—RYR2—Myometrial Relaxation and Contraction Pathways—GNAQ—melanoma	0.000865	0.0271	CbGpPWpGaD
Hydralazine—Body temperature increased—Docetaxel—melanoma	0.000838	0.00195	CcSEcCtD
Hydralazine—Hypersensitivity—Docetaxel—melanoma	0.000781	0.00181	CcSEcCtD
Hydralazine—RYR2—Transmembrane transport of small molecules—SLC15A2—melanoma	0.000753	0.0236	CbGpPWpGaD
Hydralazine—Pruritus—Docetaxel—melanoma	0.00075	0.00174	CcSEcCtD
Hydralazine—Diarrhoea—Docetaxel—melanoma	0.000725	0.00168	CcSEcCtD
Hydralazine—RYR2—Transmembrane transport of small molecules—SLC17A5—melanoma	0.000725	0.0227	CbGpPWpGaD
Hydralazine—Dizziness—Docetaxel—melanoma	0.000701	0.00163	CcSEcCtD
Hydralazine—Vomiting—Docetaxel—melanoma	0.000674	0.00156	CcSEcCtD
Hydralazine—Rash—Docetaxel—melanoma	0.000668	0.00155	CcSEcCtD
Hydralazine—Dermatitis—Docetaxel—melanoma	0.000668	0.00155	CcSEcCtD
Hydralazine—Headache—Docetaxel—melanoma	0.000664	0.00154	CcSEcCtD
Hydralazine—RYR2—SIDS Susceptibility Pathways—IL10—melanoma	0.00066	0.0206	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—SLC6A11—melanoma	0.000658	0.0206	CbGpPWpGaD
Hydralazine—RYR2—Calcium Regulation in the Cardiac Cell—PRKCA—melanoma	0.000649	0.0203	CbGpPWpGaD
Hydralazine—Nausea—Docetaxel—melanoma	0.000629	0.00146	CcSEcCtD
Hydralazine—RYR2—Myometrial Relaxation and Contraction Pathways—PRKCA—melanoma	0.000629	0.0197	CbGpPWpGaD
Hydralazine—RYR2—Arrhythmogenic Right Ventricular Cardiomyopathy—CTNNB1—melanoma	0.000604	0.0189	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—HIF1A—melanoma	0.000556	0.0174	CbGpPWpGaD
Hydralazine—CYP3A4—Liver X Receptor Pathway—FASN—melanoma	0.000417	0.013	CbGpPWpGaD
Hydralazine—CYP3A4—Benzo(a)pyrene metabolism—CYP1B1—melanoma	0.000413	0.0129	CbGpPWpGaD
Hydralazine—CYP3A4—Codeine and Morphine Metabolism—ABCB1—melanoma	0.000374	0.0117	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—CXCL8—melanoma	0.000361	0.0113	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—CASP3—melanoma	0.000345	0.0108	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—CTNNB1—melanoma	0.000333	0.0104	CbGpPWpGaD
Hydralazine—RYR2—Myometrial Relaxation and Contraction Pathways—NFKB1—melanoma	0.000325	0.0102	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—NFKB1—melanoma	0.000323	0.0101	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—SLC5A5—melanoma	0.000301	0.00942	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—VEGFA—melanoma	0.000293	0.00917	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—TNF—melanoma	0.000251	0.00786	CbGpPWpGaD
Hydralazine—CYP3A4—Estrogen metabolism—CYP1B1—melanoma	0.000237	0.00742	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—ABCB1—melanoma	0.00023	0.00718	CbGpPWpGaD
Hydralazine—CYP3A4—Tamoxifen metabolism—CYP1B1—melanoma	0.00021	0.00656	CbGpPWpGaD
Hydralazine—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—melanoma	0.000205	0.0064	CbGpPWpGaD
Hydralazine—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—melanoma	0.000204	0.00639	CbGpPWpGaD
Hydralazine—RYR2—Myometrial Relaxation and Contraction Pathways—IL6—melanoma	0.000204	0.00637	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—IL6—melanoma	0.000203	0.00634	CbGpPWpGaD
Hydralazine—CYP3A4—Irinotecan Pathway—APC—melanoma	0.000172	0.00539	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—ALB—melanoma	0.000144	0.00449	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—UGT2B10—melanoma	0.000139	0.00435	CbGpPWpGaD
Hydralazine—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—melanoma	0.000123	0.00386	CbGpPWpGaD
Hydralazine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—melanoma	0.000117	0.00368	CbGpPWpGaD
Hydralazine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—melanoma	0.000117	0.00367	CbGpPWpGaD
Hydralazine—CYP3A4—Tryptophan metabolism—CYP1B1—melanoma	0.000112	0.0035	CbGpPWpGaD
Hydralazine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP17A1—melanoma	0.000108	0.00337	CbGpPWpGaD
Hydralazine—CYP3A4—Oxidation by Cytochrome P450—CYP17A1—melanoma	0.000106	0.00332	CbGpPWpGaD
Hydralazine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—melanoma	9.06e-05	0.00283	CbGpPWpGaD
Hydralazine—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—melanoma	8.94e-05	0.0028	CbGpPWpGaD
Hydralazine—CYP3A4—Metapathway biotransformation—AKR1B10—melanoma	8.84e-05	0.00276	CbGpPWpGaD
Hydralazine—CYP3A4—Phase 1 - Functionalization of compounds—CYP17A1—melanoma	8.72e-05	0.00273	CbGpPWpGaD
Hydralazine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—melanoma	8.17e-05	0.00256	CbGpPWpGaD
Hydralazine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—melanoma	7.34e-05	0.0023	CbGpPWpGaD
Hydralazine—CYP3A4—Tryptophan metabolism—MDM2—melanoma	5.24e-05	0.00164	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—CYP17A1—melanoma	4.63e-05	0.00145	CbGpPWpGaD
Hydralazine—CYP3A4—Metapathway biotransformation—CYP17A1—melanoma	4.57e-05	0.00143	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—CYP1B1—melanoma	3.9e-05	0.00122	CbGpPWpGaD
Hydralazine—CYP3A4—Metapathway biotransformation—CYP1B1—melanoma	3.85e-05	0.0012	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ACER3—melanoma	2.6e-05	0.000813	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—UGT2B10—melanoma	2.38e-05	0.000744	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—HS3ST5—melanoma	2.21e-05	0.000692	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PLCB4—melanoma	1.68e-05	0.000524	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PIP4K2A—melanoma	1.58e-05	0.000493	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—SLC6A11—melanoma	1.58e-05	0.000493	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—MTAP—melanoma	1.53e-05	0.000479	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—LUM—melanoma	1.37e-05	0.000427	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PHGDH—melanoma	1.37e-05	0.000427	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—HPSE—melanoma	1.34e-05	0.000419	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CUBN—melanoma	1.31e-05	0.000411	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—SDHD—melanoma	1.27e-05	0.000397	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CSPG4—melanoma	1.27e-05	0.000397	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—BSG—melanoma	1.27e-05	0.000397	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—GPAM—melanoma	1.23e-05	0.000385	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PLA2G6—melanoma	1.05e-05	0.000327	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—VCAN—melanoma	9.39e-06	0.000294	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CYP17A1—melanoma	7.92e-06	0.000248	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—GNA11—melanoma	7.48e-06	0.000234	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—FASN—melanoma	7.32e-06	0.000229	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—SLC5A5—melanoma	7.2e-06	0.000225	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—GNAQ—melanoma	6.96e-06	0.000218	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CD44—melanoma	6.96e-06	0.000218	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CYP1B1—melanoma	6.67e-06	0.000209	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ABCB1—melanoma	5.49e-06	0.000172	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PRKCA—melanoma	5.05e-06	0.000158	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ERCC2—melanoma	5.01e-06	0.000157	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PIK3CG—melanoma	3.96e-06	0.000124	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PPARG—melanoma	3.82e-06	0.00012	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PIK3CD—melanoma	3.48e-06	0.000109	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ALB—melanoma	3.44e-06	0.000108	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PIK3CB—melanoma	3.03e-06	9.49e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PTGS2—melanoma	3.01e-06	9.41e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PTEN—melanoma	2.62e-06	8.2e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PIK3CA—melanoma	1.85e-06	5.79e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—AKT1—melanoma	1.51e-06	4.73e-05	CbGpPWpGaD
